Navigation Links
China Biologic Products to Participate in the Rodman & Renshaw Annual Global Investment Conference
Date:9/3/2009

TAI'AN, China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that the Company's management team will attend the upcoming Rodman & Renshaw Annual Global Investment Conference.

The date, time and location of China Biologic's presentation at the conference are as follows:

    Date:           Thursday, September 10, 2009
    Time:           12.05 p.m. Eastern Time
    Venue:          Asia Track
                    New York Palace Hotel
                    New York, NY

During the conference, the Company will be available to meet with analysts and portfolio managers. Interested parties and investors who wish to meet with China Biologic's management may contact mwoodson@rodm.com or call (212) 430-1782. Participation in the Rodman & Renshaw Annual Global Investment Conference is by invitation only.

About Rodman & Renshaw, LLC.

Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant capital needs, along with research and sales and trading services to investor clients. Rodman is a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets according to PrivateRaise a service of DealFlow Media Inc. and Sagient Research Systems, Inc.

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. It sells its products to hospitals and other healthcare facilities in China.

    For more information, please contact:

    Company Contact:
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     China Biologic Products, Inc.
     Tel:   +86-538-6202206
     Email: IR@chinabiologic.com
     Web:  http://www.chinabiologic.com

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY office) or
     Mr. Gary Chin
     Tel:   +1-646-213-1909
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes
2. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
3. AOBOs Products Included in Chinas Essential Drug List
4. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
5. China Medical Technologies to Announce Unaudited Financial Results for the Fourth Fiscal Quarter and Fiscal Year ended March 31, 2009 and the First Fiscal Quarter ended June 30, 2009 on September 1, 2009
6. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
7. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
8. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
9. China Biologic Products Schedules 2009 Second Quarter Earnings Conference Call
10. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
11. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 NanoStruck ... (OTCPink: NSKQB) ( Frankfurt : 8NSK) ... Pressemitteilung vom 13. August 2015 die Genehmigung von ... um zusätzliche 200.000.000 Einheiten auf 400.000.000 Einheiten zu ... bringen. Davon wurden 157.900.000 Einheiten mit dem ersten ...
(Date:4/27/2016)... ... 2016 , ... PathSensors, Inc., a leading environmental testing company, ... assist PathSensors in expanding the use of the company’s CANARY® technology in the ... for the detection of harmful pathogens, including a number of bacteria, viruses, toxins, ...
(Date:4/27/2016)... 27, 2016 MedDay, a biotechnology company ... the appointment of Catherine Moukheibir as Chairman of its Board ... Jean Jacques Garaud , who contributed to the rapid ... immediately. Catherine started her career in strategy consulting ... London .  She held C-Suite level roles ...
(Date:4/26/2016)... ... 2016 , ... The European Patent Office (EPO) today announced that ... for the European Inventor Award 2016 in the category "Non-European countries." The winners of ... ceremony in Lisbon on June 9th. , The human capacity to walk with fluidity ...
Breaking Biology Technology:
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
(Date:3/10/2016)... --  Unisys Corporation (NYSE: UIS ) today announced ... testing its biometric identity solution at the Otay Mesa border ... identify certain non-U.S. citizens leaving the country. ... determine the efficiency and accuracy of using biometric technologies in ... until May 2016. --> the United States ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):